Search - tctmd.com

Displaying 81 - 100 of 105

Sort: Relevancy | Date

Presentation TVT 2014

Why Cerebral Protection after TAVR Will be Used Sparingly (if at all) in the Future

Presenter: Ganesh Manoharan

June 07, 2014

Presentation TVT 2014

A Rationale Approach to Adjunct Pharmacotherapy After TAVR (With Stroke in Mind)

Presenter: Susheel Kodali

June 07, 2014

Presentation TVT 2014

Has Stroke Frequency Declined After TAVR?

Presenter: Nicolas M. van Mieghem

June 07, 2014

Presentation TVT 2014

Perspectives from the US CoreValve Trials

Presenter: Jeffrey J. Popma

June 07, 2014

Presentation TVT 2014

Perspectives from the PARTNER Trials

Presenter: Susheel Kodali

June 07, 2014

Presentation TVT 2014

Incidence, Timing, Predictors (New Onset AF, Postdilatation, etc.), and Clinical Impact

Presenter: Samir R. Kapadia

June 07, 2014

Presentation TVT 2014

Stroke Basics after Cardiovascular Interventions: VARC 2 Definitions, Stroke Severity Assessment, Neuroimaging, and Neurocognitive Function

Presenter: Martin B. Leon

June 07, 2014

Presentation TVT 2013

Sentreheart: A Leap from Ligation to Stroke Reduction: Treatment Recommendations in the Absence of a Trial

Presenter: William Gray

June 15, 2013

Presentation TVT 2013

The Keystone Deflector Device: Technology and Early Clinical Experiences

Presenter: Jeffrey Moses

June 12, 2013

Presentation TVT 2013

The Embrella Deflector Device: Technology and Early Clinical Experiences

Presenter: John Webb

June 12, 2013

Presentation TVT 2013

The Claret Montage Filter Device: Technology and Early Clinical Experiences

Presenter: Eberhard Grube

June 12, 2013

Presentation TVT 2013

Taking Strokes Seriously: Definitions (VARC 2), Stroke Grading Scores, Study Endpoints, Neuroimaging, and Neurocognitive Function

Presenter: Martin Leon

June 12, 2013

Presentation TVT 2013

Stroke Frequency and Timing after TAVR: Evolving Insights from the PARTNER Database

Presenter: Samir Kapadia

June 12, 2013

Presentation TVT 2013

Status Update of the PROTAVI C Trial in EU

Presenter: Alec Vahanian

June 12, 2013

Presentation TVT 2013

Predictors of TAVR: Associated Strokes: New Onset Atrial Fibrillation, Postdilatation, and Others

Presenter: Josep Rodes-Cabau

June 12, 2013

Presentation TVT 2013

Pharmacotherapy Alternatives During and After TAVR: Is There an Optimal Regimen?

Presenter: Corrado Tamburino

June 12, 2013

Presentation TVT 2013

Pathoanatomic Findings from Filtered Debris After TAVR

Presenter: Nicolas van Mieghem

June 12, 2013

Presentation TVT 2012

The Evolving Standard of Care: Oral Antithrombotic Agents for Stroke Prevention in Atrial Fibrillation

Presenter: Gregg Stone

June 05, 2012

Presentation TVT 2012

Left Atrial Appendage Anatomy: An Anatomical Imaging Review and Implications for Stroke Prevention

Presenter: Rebecca Hahn

June 05, 2012

Presentation TVT 2012

Will Cerebral Embolic Protection Devices Reduce Strokes After TAVR?

Presenter: Josep Rodes-Cabau

June 04, 2012

Advertisement

Why Cerebral Protection after TAVR Will be Used Sparingly (if at all) in the Future

A Rationale Approach to Adjunct Pharmacotherapy After TAVR (With Stroke in Mind)

Has Stroke Frequency Declined After TAVR?

Perspectives from the US CoreValve Trials

Perspectives from the PARTNER Trials

Incidence, Timing, Predictors (New Onset AF, Postdilatation, etc.), and Clinical Impact

Stroke Basics after Cardiovascular Interventions: VARC 2 Definitions, Stroke Severity Assessment, Neuroimaging, and Neurocognitive Function

Sentreheart: A Leap from Ligation to Stroke Reduction: Treatment Recommendations in the Absence of a Trial

The Keystone Deflector Device: Technology and Early Clinical Experiences

The Embrella Deflector Device: Technology and Early Clinical Experiences

The Claret Montage Filter Device: Technology and Early Clinical Experiences

Taking Strokes Seriously: Definitions (VARC 2), Stroke Grading Scores, Study Endpoints, Neuroimaging, and Neurocognitive Function

Stroke Frequency and Timing after TAVR: Evolving Insights from the PARTNER Database

Status Update of the PROTAVI C Trial in EU

Predictors of TAVR: Associated Strokes: New Onset Atrial Fibrillation, Postdilatation, and Others

Pharmacotherapy Alternatives During and After TAVR: Is There an Optimal Regimen?

Pathoanatomic Findings from Filtered Debris After TAVR

The Evolving Standard of Care: Oral Antithrombotic Agents for Stroke Prevention in Atrial Fibrillation

Left Atrial Appendage Anatomy: An Anatomical Imaging Review and Implications for Stroke Prevention

Will Cerebral Embolic Protection Devices Reduce Strokes After TAVR?

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content